Latest news with #UnitedTherapeuticsCorporation
Associated Press
2 days ago
- Business
- Associated Press
Investors Who Lost Money on 3D Systems Corporation (DDD) Should Contact Levi & Korsinsky About Pending Class Action
NEW YORK - July 21, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in 3D Systems Corporation ('3D Systems Corporation' or the 'Company') (NYSE: DDD) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of 3D Systems Corporation investors who were adversely affected by alleged securities fraud between August 13, 2024 and May 12, 2025. Follow the link below to get more information and be contacted by a member of our team: DDD investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) 3D Systems had understated the impact of weakened customer spending on the Company's business, while overstating its resilience in challenging industry conditions; (ii) in addition, the updated milestone criteria in the partnership with United Therapeutics Corporation would negatively impact the Company's regenerative medicine program revenue; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times. WHAT'S NEXT? If you suffered a loss in 3D Systems Corporation during the relevant time frame, you have until August 12, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To learn more about this case, subscribe to the Bulls & Betrayals podcast, which features a dedicated episode unpacking the allegations against 3D Systems Corporation. Listen now and find out if you are eligible to join the lawsuit. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. Ed Korsinsky, Esq. 33 Whitehall Street, 17th Floor New York, NY 10004 [email protected] Tel: (212) 363-7500 Fax: (212) 363-7171
Yahoo
11-04-2025
- Health
- Yahoo
Transplanted pig kidney removed after functioning in living patient for more than four months
A genetically engineered pig kidney helped Towana Looney enjoy 130 days without the need for dialysis before the organ was removed last week. It's the longest a human has ever lived with a pig organ, marking another step forward in the burgeoning field of xenotransplantation, or the practice of transplanting animal organs into humans. Looney, a 53-year-old-woman from Alabama, had been on dialysis for nine years before she received the pig kidney transplant in late November, becoming only the third person to receive a kidney from a gene-edited pig while alive. She left the hospital 11 days after surgery at NYU Langone Transplant Institute, staying at an apartment near the hospital so she could get checkups every day. But medical complications developed after months of stability, leading to the difficult decision to remove the organ on April 4. 'In early April, she had a reduction in renal function due to acute rejection. What triggered the rejection episode after a long period of stability is being actively investigated, but it followed a lowering of her immunosuppression regimen to treat an infection unrelated to the pig kidney,' Dr. Robert Montgomery, director of the NYU Langone Transplant Institute and chair of NYU Langone Health's surgery department, said in a statement. 'The decision was made by Ms. Looney and her doctors that the safest intervention would be to remove the kidney and return to dialysis rather than giving additional immunosuppression. This preserves future possibilities for transplantation for her as knowledge and innovations progress,' he said. United Therapeutics Corporation, the biotech company that developed the modified pig kidney – known as a UKidney – celebrated the bravery and enthusiasm Looney has shown throughout the xenotransplantation journey. 'One of the biggest challenges for transplant recipients – human-to-human or pig-to-human – is the prevention and management of infections while simultaneously balancing the level of immunosuppression medications required to prevent rejection, especially in the first months after surgery,' the company said in a statement. 'We will learn more about the circumstances that led to removal of the UKidney, but current evidence suggests that the UKidney functioned well up until the time of rejection, which appears to have occurred due to a reduction in immunosuppression while treating infection unrelated to the xenokidney,' they said. 'We expect physicians at NYU will share their findings in a peer-reviewed publication in the future.' Looney donated a kidney to help save her mother's life in 1999 but later developed kidney failure after her remaining kidney was damaged by preeclampsia, a serious pregnancy complication involving persistent high blood pressure. After years on the waitlist for an organ transplant, she began to develop problems associated with chronic dependence on dialysis. Without a donor match, she would die – but the complications she had developed made it more difficult to find one. When she heard about the option to try a pig kidney transplantation, she jumped at the chance to try it. 'Without a pathway to receiving a human kidney, she decided a gene-edited pig kidney was worth a try, and a lot of people rallied around her decision, including her husband and family,' Montgomery said at the time. Looney is now back home in Alabama and says she's grateful for the opportunity she had to participate in the research. 'For the first time since 2016, I enjoyed time with friends and family without planning around dialysis treatments,' she said in a statement. 'Though the outcome is not what anyone wanted, I know a lot was learned from my 130 days with a pig kidney – and that this can help and inspire many others in their journey to overcome kidney disease. I remain thankful to all of the doctors and researchers at NYU Langone for all they are doing.' More than 90,000 people in the United States are on the waitlist to receive a kidney transplant, according to data from the Organ Procurement and Transplantation Network, accounting for the vast majority of people waiting to receive an organ donation. The average wait time for a kidney is three to five years at most centers, and about 13 people die each day waiting. Dialysis – a procedure to help remove waste and extra fluid from the blood – can be helpful in the short term but can do only 10% to 15% of what a healthy kidney does, and people on dialysis have a 50% chance of dying in the five years after they start the treatment, studies show. The US Food and Drug Administration allows doctors to transplant organs from pigs into humans under what's commonly known as 'compassionate use,' which permits use of an experimental therapy or procedure if 'comparable or satisfactory' options aren't available. Pigs' organs are similar to humans', and the speed of pigs' reproduction means their organs can be procured quickly. Scientists can edit the genes of the pig to reduce the risk that a human body will reject its organ. Of the three people to receive a kidney from a gene-edited pig while alive, Looney was the first to receive a kidney with 10 gene edits, and United Therapeutics announced in February that it was cleared by the FDA to use this type of pig kidney in the first human clinical trials to study xenotransplantation. The company says they are in regular contact with the FDA about this and expect to perform the first of six initial transplants in people with end-stage kidney disease in the middle of 2025, with the intent of expanding the trial to a total of 50 patients. Some experts foresee pig kidney transplant becoming an established option for patients within a decade, a major advancement that would be possible because of people like Looney. 'Towana's willingness to endeavor into the unknown to help solve the nation's organ shortage crisis will impact many more lives after her. We celebrate her tremendous courage and sacrifice,' Montgomery said. 'She lived with a pig kidney longer than any other human in history, and the field has learned a great deal from her. Her contribution has furthered the hope and promise of genetically engineered pig organs as an alternative source to human organs.' United Therapeutics echoed the same sentiment. 'Mrs. Looney's bravery has enabled major advancements in the field of xenotransplantation and adds to the foundational insights made possible by the contributions of other patients. Her case will continue to add to the scientific community's understanding of xenotransplantation, from the initial transplant procedure to the post-transplant management of the xenograft,' the company said. 'We keep Mrs. Looney and her family in our thoughts, and we wish her a speedy recovery.' CNN's Amanda Sealy contributed to this report.
CNN
11-04-2025
- Health
- CNN
Transplanted pig kidney removed after functioning in living patient for more than four months
A genetically engineered pig kidney helped Towana Looney enjoy 130 days without the need for dialysis before the organ was removed last week. It's the longest a human has ever lived with a pig organ, marking another step forward in the burgeoning field of xenotransplantation, or the practice of transplanting animal organs into humans. Looney, a 53-year-old-woman from Alabama, had been on dialysis for nine years before she received the pig kidney transplant in late November, becoming only the third person to receive a kidney from a gene-edited pig while alive. She left the hospital 11 days after surgery at NYU Langone Transplant Institute, staying at an apartment near the hospital so she could get checkups every day. But medical complications developed after months of stability, leading to the difficult decision to remove the organ on April 4. 'In early April, she had a reduction in renal function due to acute rejection. What triggered the rejection episode after a long period of stability is being actively investigated, but it followed a lowering of her immunosuppression regimen to treat an infection unrelated to the pig kidney,' Dr. Robert Montgomery, director of the NYU Langone Transplant Institute and chair of NYU Langone Health's surgery department, said in a statement. 'The decision was made by Ms. Looney and her doctors that the safest intervention would be to remove the kidney and return to dialysis rather than giving additional immunosuppression. This preserves future possibilities for transplantation for her as knowledge and innovations progress,' he said. United Therapeutics Corporation, the biotech company that developed the modified pig kidney – known as a UKidney – celebrated the bravery and enthusiasm Looney has shown throughout the xenotransplantation journey. 'One of the biggest challenges for transplant recipients – human-to-human or pig-to-human – is the prevention and management of infections while simultaneously balancing the level of immunosuppression medications required to prevent rejection, especially in the first months after surgery,' the company said in a statement. 'We will learn more about the circumstances that led to removal of the UKidney, but current evidence suggests that the UKidney functioned well up until the time of rejection, which appears to have occurred due to a reduction in immunosuppression while treating infection unrelated to the xenokidney,' they said. 'We expect physicians at NYU will share their findings in a peer-reviewed publication in the future.' Looney donated a kidney to help save her mother's life in 1999 but later developed kidney failure after her remaining kidney was damaged by preeclampsia, a serious pregnancy complication involving persistent high blood pressure. After years on the waitlist for an organ transplant, she began to develop problems associated with chronic dependence on dialysis. Without a donor match, she would die – but the complications she had developed made it more difficult to find one. When she heard about the option to try a pig kidney transplantation, she jumped at the chance to try it. 'Without a pathway to receiving a human kidney, she decided a gene-edited pig kidney was worth a try, and a lot of people rallied around her decision, including her husband and family,' Montgomery said at the time. Looney is now back home in Alabama and says she's grateful for the opportunity she had to participate in the research. 'For the first time since 2016, I enjoyed time with friends and family without planning around dialysis treatments,' she said in a statement. 'Though the outcome is not what anyone wanted, I know a lot was learned from my 130 days with a pig kidney – and that this can help and inspire many others in their journey to overcome kidney disease. I remain thankful to all of the doctors and researchers at NYU Langone for all they are doing.' More than 90,000 people in the United States are on the waitlist to receive a kidney transplant, according to data from the Organ Procurement and Transplantation Network, accounting for the vast majority of people waiting to receive an organ donation. The average wait time for a kidney is three to five years at most centers, and about 13 people die each day waiting. Dialysis – a procedure to help remove waste and extra fluid from the blood – can be helpful in the short term but can do only 10% to 15% of what a healthy kidney does, and people on dialysis have a 50% chance of dying in the five years after they start the treatment, studies show. The US Food and Drug Administration allows doctors to transplant organs from pigs into humans under what's commonly known as 'compassionate use,' which permits use of an experimental therapy or procedure if 'comparable or satisfactory' options aren't available. Pigs' organs are similar to humans', and the speed of pigs' reproduction means their organs can be procured quickly. Scientists can edit the genes of the pig to reduce the risk that a human body will reject its organ. Of the three people to receive a kidney from a gene-edited pig while alive, Looney was the first to receive a kidney with 10 gene edits, and United Therapeutics announced in February that it was cleared by the FDA to use this type of pig kidney in the first human clinical trials to study xenotransplantation. The company says they are in regular contact with the FDA about this and expect to perform the first of six initial transplants in people with end-stage kidney disease in the middle of 2025, with the intent of expanding the trial to a total of 50 patients. Some experts foresee pig kidney transplant becoming an established option for patients within a decade, a major advancement that would be possible because of people like Looney. 'Towana's willingness to endeavor into the unknown to help solve the nation's organ shortage crisis will impact many more lives after her. We celebrate her tremendous courage and sacrifice,' Montgomery said. 'She lived with a pig kidney longer than any other human in history, and the field has learned a great deal from her. Her contribution has furthered the hope and promise of genetically engineered pig organs as an alternative source to human organs.' United Therapeutics echoed the same sentiment. 'Mrs. Looney's bravery has enabled major advancements in the field of xenotransplantation and adds to the foundational insights made possible by the contributions of other patients. Her case will continue to add to the scientific community's understanding of xenotransplantation, from the initial transplant procedure to the post-transplant management of the xenograft,' the company said. 'We keep Mrs. Looney and her family in our thoughts, and we wish her a speedy recovery.' CNN's Amanda Sealy contributed to this report.
Yahoo
10-04-2025
- Business
- Yahoo
11 Stocks to Anchor Your Portfolio Amid Wild Market Volatility
Stock markets posted a historic rebound on Wednesday. Caution remains the watchword as tariffs continue to impact futures. Weather the market storm with smart stock picks using the screener. Looking for more actionable trade ideas to navigate the current market volatility? . The markets staged a spectacular rebound on Wednesday, with the Dow Jones up 7.87%, the S&P 500 +9.52% and the Nasdaq +12.16%, as Donald Trump paused the tariffs announced last week for many countries. For the S&P 500, it was the biggest one-day rise since 2008 and the third-biggest in post-war history. For the Dow Jones, it was its biggest rise since March 2020. Finally, the Nasdaq posted its biggest one-day rise since January 2001 and its second-best day ever. However, at the time of writing, sellers already seem to be gaining the upper hand, with the S&P 500 down over 2.2% on futures markets at the time of writing. Indeed, the suspension of tariffs announced last night has a major downside: China is not affected by the suspension and was even hit last night with new 125% tariffs as part of a US overbid following Beijing's retaliation to Trump's earlier announcements. What's more, market veterans know that all major crashes include respite sessions like the one seen yesterday. The Nasdaq Composite jumped 14.17% in January 2001, in the midst of the dot-com crash. And during the financial crisis of October 2008, the Nasdaq had two of its best five days ever. To sum up, caution is still the order of the day, and market turbulence is likely to continue despite yesterday's bullish explosion. Against this backdrop, investors should continue to be cautious in their stock choices, and favor the safest bets. So, using the screener, we can find solid stocks that could currently be good buying opportunities. To do this, we began by using the pre-configured "Financial Fortresses" screner, which identifies stocks meeting the following criteria: The search revealed 357 stocks on the US market. We wanted to refine this search by adding an additional criterion: Bullish potential of over 25% according to InvestingPro Fair Value. Remember: InvestingPro Fair Value calculates an intelligent blend of several recognized valuation models for each stock on the market. We have also modified the capitalization criterion to exclude companies valued at less than $10 billion. Finally, we have also prioritized quality by raising the minimum accepted Piotroski score to 8. With these modifications, the search now returns only : Among these stocks, United Therapeutics Corporation (NASDAQ:UTHR) has the "lowest" potential, at +26.8%. On the other hand, it has the strongest profile according to the criteria taken into account, with a perfect Piotroski score of 9 and the highest health score among the stocks on the list, at 3.93 / 5. Barrick Gold Corp (NYSE:GOLD), one of the biggest gold stocks in terms of capitalization, also makes the list, with a 28.8% bullish potential according to Fair Value, a Piotroski score of 8, and a health score of 3.25 / 5. However, there are stocks on this list with much higher potential. Specifically, this research contains 6 stocks with upward potential of over 40%, according to Fair Value, including one that could even rise by over 68% according to the models. With solid financial health and considerable upside potential, these stocks could be the wisest choices to weather the current period of high volatility and uncertainty and even profit from it. For those who know how to keep a cool head, stock market crashes are indeed ideal opportunities to acquire at low prices quality stocks that have been unfairly punished during panic movements. Indeed, whether markets are rising or falling, there are always opportunities to be seized by those who know how to look. So, with the right method and the right research tools, such as the screener and InvestingPro's exclusive indicators, investors can emerge stronger from crises. The research in this article is just one example. In fact, the screener offers over 20 pre-configured searches (note that many of these searches are reserved for InvestingPro subscribers, Pro+ plan!), which can be expanded using over 1,200 different indicators and metrics (Pro+ subscribers have access to 160 indicators). Of course, it's possible to create your own searches without using a pre-configured screener and save them so you can come back to them later and refine them as the markets evolve. *** Disclaimer: This article is written for informational purposes only. It is not intended to encourage the purchase of assets in any way, nor does it constitute a solicitation, offer, recommendation or suggestion to invest. I would like to remind you that all assets are evaluated from multiple perspectives and are highly risky, so any investment decision and the associated risk belongs to the investor. We also do not provide any investment advisory services. Related articles Hims' Weight Loss Expansion: Real Growth or Just Hype? 3 Big Banks With Strong Setups Ahead of Q1 2025 Earnings Release Q1 Earnings Season Mired in Uncertainty as Banks Begin Reporting Friday Sign in to access your portfolio
Yahoo
02-04-2025
- Business
- Yahoo
Is United Therapeutics Corporation (UTHR) The Most Profitable Biotech Stock To Buy Right Now?
We recently published a list of . In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands against other most profitable biotech stocks to buy right now. With improved market conditions, innovative breakthroughs, and more investor interest, the biotechnology industry is gaining new traction. The sector has bounced back from a difficult 2024 and is set to grow significantly, thanks to developments in AI-driven drug discovery, personalized medicine, and the rising demand for biologics. The global biotech market was expected to grow by a robust 13%, from $483.0 billion in 2024 to $546.0 billion in 2025, according to MarketsandMarkets. The sector's resilience and growth potential are demonstrated by this expansion. One of the main causes of this upturn is the expected change in the Federal Reserve's interest rate policies. Because biotech involves expensive R&D and clinical testing, it is susceptible to shifting rate patterns. According to Genetic Engineering and Biotechnology News, lower rates increase the amount of cash available, which aids biotech companies in growing, attracting venture capital, and accelerating drug development. Analysts predict that a rate decline might free up billions of dollars in investment money set aside for nascent biotech companies seeking stable funding. The global biotechnology sector is undergoing transformative growth in 2025, driven by scientific breakthroughs and shifting market dynamics. Key trends, treatments, financial metrics, and the US regulatory landscape significantly impact the industry. Genetic engineering is becoming a dominant force in biotech, with CRISPR-based therapies like Casgevy—approved for sickle cell disease and beta-thalassemia—expanding into polygenic disorders such as diabetes. Synthetic biology is also projected to experience tremendous growth, with expectations to reach $100 billion by 2030, enabling sustainable pharmaceutical and biofuel production. Another important development is AI-driven drug discovery, which has reduced drug discovery costs by 30-50% while accelerating timelines. Startups are increasingly leveraging machine learning for precision oncology and protein design. The RNA therapeutics sector is also booming, particularly following the success of mRNA vaccines, which paved the way for RNA interference (RNAi) therapies like Fitusiran. Fitusiran has shown an impressive 89.9% reduction in bleeding events in hemophilia A/B patients. Regenerative medicine is also advancing, with innovations such as 3D bioprinting and CAR-T cell therapies entering clinical trials for organ repair and cancer treatment. The regenerative medicine market is expected to reach $37.27 billion by 2031. Several biotech therapies are showing significant efficacy across various medical conditions, driving both medical advancements and investor enthusiasm. CRISPR-Cas9 treatments, aimed at genetic disorders, have over 1,200 clinical trials ongoing. mRNA vaccines, used for infectious diseases and cancer, have already administered more than 29 million doses globally by 2024. Imdelltra, a treatment for small cell lung cancer, has achieved a 40% objective response rate. It is estimated that 90,000 patients globally use gene and cell therapies annually. The biotech sector continues to thrive with groundbreaking treatments, including Imdelltra, which is projected to generate $2.1 billion in sales by 2030. Meanwhile, analysts at William Blair foresee significant potential for zanzalintinib, estimating it could reach $5 billion in net U.S. sales by 2033. This promising drug is expected to target multiple indications, such as renal cell carcinoma, colorectal cancer, neuroendocrine tumors, and head-and-neck cancer, further solidifying its blockbuster status. As these groundbreaking innovations reshape the medical landscape, they are also fueling a surge in investor interest in biotech equities, positioning the industry as a high-growth space despite its inherent volatility. Leading investment banks, including Goldman Sachs, see biotech as an 'undervalued opportunity' with strong fundamentals, improved clinical outcomes, and favorable regulations. JPMorgan analysts anticipate a rebound in biotech funding, with signs of stability in manufacturing and research. Declining interest rates could also reopen the IPO window for biotech firms. Meanwhile, innovations in gene editing, AI-powered drug discovery, and precision medicine are driving biotech's expansion, revolutionizing treatments for genetic disorders, autoimmune diseases, and cancer. For our methodology, we screened for biotech companies with a market capitalization of over $10 billion and a net income exceeding $100 million. From that group, we identified the stocks with the highest net income and ranked them accordingly. At Insider Monkey, we are obsessed with hedge funds. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here). A team of scientists in a laboratory, running tests on a biotechnology product. Latest Net Income: $1.20 billion United Therapeutics Corporation (NASDAQ:UTHR) is a biotechnology company specializing in treatments for rare and life-threatening diseases, primarily pulmonary arterial hypertension (PAH) and cardiovascular disorders. Its main drugs, Tyvaso, Orenitram, and Remodulin, are marketed to patients, hospitals, and specialized pharmacies. In 2024, United Therapeutics Corporation (NASDAQ:UTHR) exceeded forecasts with record revenue and robust earnings. The business exceeded forecasts of $6.10 with earnings per share (EPS) of $6.19. The financial performance was aided by double-digit growth in important drugs such as Unituxin, Tyvaso, Remodulin, and Orenitram. United Therapeutics Corporation (NASDAQ:UTHR)'s Tyvaso revenue grew 19% year-over-year to $4 million in Q4, while Orenitram saw a 28% increase to $108 million. Remodulin saw a 17% increase in global sales of $135 million, while Unituxin saw a 25% increase in sales, reaching a record $68 million. These profits demonstrate how well-positioned the company is in the market for treating rare disorders like pulmonary arterial hypertension (PAH). United Therapeutics Corporation (NASDAQ:UTHR) improved its clinical pipeline in addition to growing financially. The first FDA-approved xenotransplantation trial for organ replacement was the uKidney clinical trial, for which the business obtained IND permission. Confidence in long-term growth and innovation is strengthened by capital allocation that is balanced between strategic investments, acquisitions, and shareholder returns through repurchase plans. Overall, UTHR ranks 2nd on our list of most profitable biotech stocks to buy right now. While we acknowledge the potential of biotech companies, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than UTHR but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
